English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dalbavancin and comparators were susceptibility tested against 8643 Gram-positive bacteria from 74 hospitals located in Europe and the United States by broth microdilution method. The most common organisms were  Staphylococcus aureus  (45.2%),  Enterococcus faecalis  (12.2%), and  Staphylococcus epidermidis  (8.9%), but rank order varied markedly by geographic region. Dalbavancin demonstrated potent activity and broad spectrum, with MIC 90  values of 0.03 mg/L for  Staphylococcus aureus , β-haemolytic streptococci, and viridans group streptococci; 0.06 mg/L for  Enterococcus faecalis  and  Staphylococcus epidermidis ; and 0.12 mg/L for vancomycin-susceptible  Enterococcus faecium . All organisms, except vancomycin-resistant enterococci and 1  Staphylococcus haemolyticus  isolate, were inhibited at ≤ 0.25 mg/L of dalbavancin.

european journal of clinical microbiology and infectious diseases

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)